There are currently 25 clinical trials in Huntington Park, California looking for participants to engage in research studies. Trials are conducted at various facilities, including National Research Institute, National Research Institute - Huntington Park, Investigational Site Number 840070 and Velocity Clinical Research, Huntington Park. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
Recruiting
This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
03/26/2024
Locations: Research Site, Huntington Park, California
Conditions: Chronic Kidney Disease With High Proteinuria
Enlighten Study: The EV-ICD Post Approval Registry
Recruiting
Medtronic is sponsoring Enlighten: The EV-ICD Post Approval Registry, to further confirm safety and effectiveness of EV-ICD in routine clinical practice, following commercial release of EV-ICD devices.
Gender:
All
Ages:
All
Trial Updated:
03/20/2024
Locations: Cardiology Associates Medical Group, Huntington Park, California
Conditions: Ventricular Arrhythmia, Tachycardia
A Study of BION-1301 in Adults With IgA Nephropathy
Recruiting
Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: IMD Clinical Trials, Huntington Park, California
Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
Recruiting
This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have cardiovascular or chronic kidney disease. People who have at least 2 health problems related to their weight or risks of cardiovascular disease can participate. Participants must have previously tried to lose weight by changing their diet. The purpose of this study is to find out whether people with overweight or obesity who take a medicine called su... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Velocity Clinical Research, Huntington Park, California
Conditions: Obesity
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
Recruiting
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home vi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Velocity Clin Res Hunt Park, Huntington Park, California
Conditions: Diabetes Mellitus, Type 2, Obesity
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
Recruiting
The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. The main goal of the study is to compare how many people taking efinopegdutide or placebo stop showing evidence of NASH without liver scarring getting worse.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/15/2024
Locations: Velocity Clinical Research, Huntington Park ( Site 3217), Huntington Park, California
Conditions: Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Recruiting
Primary Objective: Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former smokers with moderate-to-severe COPD Evaluate the efficacy of itepekimab compared with placebo on occurrence of acute exacerbation of COPD (AECOPD) in former smokers with moderate-to-severe C... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
03/14/2024
Locations: California Research Institute Site Number : 8400400, Huntington Park, California
Conditions: Chronic Obstructive Pulmonary Disease
Phase 2b Study of GSK4532990 in Adults With NASH
Recruiting
The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/13/2024
Locations: GSK Investigational Site, Huntington Park, California
Conditions: Nonalcoholic Fatty Liver Disease
A Chronic Weight Management Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Recruiting
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/12/2024
Locations: National Research Institute - Huntington Park, Huntington Park, California
Conditions: Obesity, Overweight
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
Recruiting
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Velocity Clinical Research, Huntington Park, Huntington Park, California
Conditions: Obesity
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Recruiting
The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/05/2024
Locations: National Research Institute - Huntington Park, Huntington Park, California
Conditions: Type 2 Diabetes
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Recruiting
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis (MONARCH)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/01/2024
Locations: Site #378, Huntington Park, California
Conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)